Spruce Biosciences (SPRB)
(Delayed Data from OTC)
$0.14 USD
+0.02 (12.50%)
Updated Aug 5, 2025 03:52 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SPRB 0.14 +0.02(12.50%)
Will SPRB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SPRB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRB
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates
Illumina (ILMN) Q2 Earnings and Revenues Surpass Estimates
SPRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
NeoGenomics (NEO) Tops Q4 Earnings Estimates
Other News for SPRB
Spruce Biosciences to enact 1-for-75 reverse stock split
Spruce Biosciences (SPRB) Advances in Phase 2 Depression Treatment Trial | SPRB Stock News
Spruce, HMNC Brain Health announce first patient dosed in Phase 2 TAMARIND trial
Spruce Biosciences (SPRB) Gains Investor Attention with Significant Interest Surge | SPRB Stock News
Biotech Alert: Searches spiking for these stocks today